I. Field of the Invention
The present invention relates generally to the fields of microbiology, immunology, and antimicrobial pharmacotherapy.  More particularly the compositions and methods of the invention relate to modulation of innate immunity in the lungs of an individual for the treatment or attenuation of microbial infection or invasion using small molecule compositions. 
II.  Background
The susceptibility of the lungs to infection arises from the architectural requirements of gas exchange.  To support ventilation, humans continuously expose 100 m2 lung surface area to the external environment.  Lungs are exposed not only to air, but also to the particles, droplets, and pathogens that are suspended within it.  Unlike cutaneous surfaces that are wrapped in impermeable skin or the gastrointestinal tract with a thick adsorbent blanket of mucus, the lungs present a large environmental interface with a minimal barrier defense.  A more substantial barrier is precluded by the demand for unimpeded gaseous diffusion. 
Despite their structural vulnerability, the lungs generally defend themselves successfully against infection through a variety of mechanical, humoral, and cellular mechanisms (Knowles et al.,  2002; Martin and Frevert, 2005; Rogan, et al.,  2006; Travis, et al.,  2001); (Mizgerd, 2008; Bals and Hiemstra, 2004; Bartlett et al.,  2008; Hiemstra, 2007; Hippenstiel et al.,  2006; Schutte and McCray, 2002).  Most inhaled microbial pathogens fail to penetrate to the alveoli due to impaction against the airway walls, where they are entrapped by mucus and then expelled via the mucociliary escalator system (Knowles et al.,  2002).  For those pathogens that escape this fate, the constitutive presence of antimicrobial peptides in the airway lining fluid limits their growth (Rogan, et al.,  2006; Travis, et al.,  2001).  Alveolar macrophages that reside in the most distal airspaces are able to ingest these organisms, thereby clearing the lungs from a potential infection. 
Though often regarded as passive gas exchange barriers, the airway and alveolar epithelia supplement the baseline lung defenses by undergoing remarkable local structural and functional changes when pathogenic stimuli are encountered.  In response to viral, fungal, or allergic inflammation, airway secretory cells rapidly increase their height and fill their apical cytoplasm with secretory granules, a process termed inflammatory metaplasia (Evans et al.,  2004; Williams et al.,  2006).  In the presence of pathogens, the alveolar epithelia activate their plasmalemmal systems and secretory machinery, thereby engaging leukocytes in lung protection (Evans et al.,  2005).  Perhaps most importantly, microbial interactions with respiratory epithelial pattern recognition receptors causes numerous microbicidal products to be expressed into the airway lining fluid, including defensins, cathelicidins, lysozyme, and reactive oxygen species (Rogan et al.,  2006; Forteza et al.,  2005; Akinbi et al.,  2000; Bals and Hiemstra, 2004; Bals and Hiemstra, 2006).  It is of note that pneumonia (bacterial or viral) is the leading cause of death from infection worldwide. 
There is a need for additional methods and compositions for inhibiting and/or treating microbial infections.